Omni Commerce Corp. (TSXV:OMNI, FRA:0MZA) (“Omni” or the “Company”) announces the appointment of Alex McAulay to the board of directors of the Company, effective immediately.

“We are pleased to welcome Mr. McAulay to Omni’s board of directors,” stated Peter M. Clausi, Omni’s interim CEO, “Mr. McAulay has extensive experience in conducting due diligence and advising boards of directors with respect to merger and acquisition transactions, which will assist Omni as it works to conclude the reverse takeover with Dreamfields Brands, Inc.”


Mr. McAulay CPA, CA is an entrepreneur and experienced public-company CFO and director. Mr. McAulay’s company, ACM Management Inc., is focused on providing fractional CFO services and regulatory guidance to public companies in Canada and the US. Alex has served as the CFO of several listed companies and has assisted many issuers in navigating the public markets.

Dreamfields Transaction

The Company also announces that the outside closing date (the “Outside Date”) under the previously announced transaction agreement (the “Transaction Agreement”) with a wholly-owned subsidiary of Omni (“Omni Subco”) and Dreamfields Brands, Inc. (“Dreamfields”) has been extended from March 13, 2020 to April 10, 2020. The amendments to the Transaction Agreement were effected by way of a fourth amending agreement to the Transaction Agreement dated as of March 13, 2020, with Omni Subco and Dreamfields.

The Transaction Agreement has also been amended to reflect that the previously announced break fee (see news release dated February 18, 2020) has been increased from USD $50,000 to USD $100,000 (the “Break Fee”). The Break Fee is payable by Dreamfields if it terminates the Transaction Agreement prior to delivering the requisite financial statements to Omni, or by either party if, after Dreamfields has delivered the requisite financial statements to Omni, such party terminates the Transaction Agreement due to the closing of the transaction not having occurred on or before the Outside Date. All other terms of the Transaction Agreement remain in full force and effect.

Mr. Clausi further stated, “Omni and Dreamfields are in constant communication as we all prepare for closing. The results of our due diligence have been highly positive, and with closing expected to take place in the near future, Mr. McAulay will help us complete our work in a timely manner.”

About Omni

Omni is a publicly listed company currently listed on the TSX Venture Exchange, trading under the symbol “OMNI”. Omni is headquartered in Vancouver, British Columbia and is a reporting issuer in British Columbia and Alberta.

ON BEHALF OF THE BOARD

OMNI COMMERCE CORP.

Per: “Peter M. Clausi”
Peter M. Clausi, President & CEO

For further information, please contact:

Anthony Balic, CFO
Phone: (604) 312-2425
Email: abalic@katunicapital.com

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release.

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, “forward-looking statements”) within the meaning of applicable Canadian legislation. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future. Although the Company believes that such statements are reasonable and reflect expectations of future developments and other factors which management believes to be reasonable and relevant, the Company can give no assurance that such expectations will prove to be correct. Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements. Any forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements.

Source

Inaugural runs of the award-winning and new white-label brands will allow the infused beverage expert to move ahead quickly with commercialization plans

Emerging leader in infused cannabis beverages, BevCanna Enterprises Inc. (CSE:BEV) (OTCQB:BVNNF) (FSE:7BC) (“BevCanna” or the “Company”) is pleased to announce that it has successfully completed the R&D and trial production runs of its exclusively licenced award winning line of Keef Beverages and the white-label beverages the Company is producing for State B Beverages.

Keep reading... Show less

(TheNewswire)

Keep reading... Show less

Revive Therapeutics Ltd. (“Revive” or the “Company”) (CSE: RVV, USA: RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce an update on the Company’s U.S. Food & Drug Administration (“U.S. FDA”) Phase 3 clinical trial (the “Study”) to evaluate the safety and efficacy of Bucillamine in patients with mild-moderate COVID-19. The Company has committed to ten clinical sites across Florida, Texas, Nevada, Arizona and California, and it is estimated that over 200 patients will have completed the Study for the interim analysis by the end of December 2020. The interim analysis will determine the better performing Bucillamine dose arm for the remainder of the trial and future complementary studies evaluating it in more severe cases, thus making Bucillamine a potential treatment option.

“We are one of a few life sciences companies evaluating an investigational drug in a Phase 3 clinical trial for COVID-19 and with the rising prevalence of cases throughout the U.S., we are confident that our targets will be achieved to support the potential FDA approval and commercialization of Bucillamine for the treatment of the virus,” said Michael Frank, Revive’s Chief Executive Officer.

Keep reading... Show less

Nextleaf Solutions Ltd. (CSE: OILS) (OTCQB: OILFF) (“Nextleaf”, “OILS”, or the “Company”), Canada’s most innovative cannabis extractor, is pleased to provide shareholders with the following commercial update:

Vape Cartridges Powered by OILSTM now Available in the Provincial Retail Market

Keep reading... Show less

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Aurora Cannabis Inc. (NYSE: ACB) between February 13, 2020 and September 4, 2020, inclusive (the “Class Period”), of the important December 1, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Aurora investors under the federal securities laws.

To join the Aurora class action, go to http://www . rosenlegal.com/cases-register-1965.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email pkim@rosenlegal.com or cases@rosenlegal.com for information on the class action.

Keep reading... Show less